ATD治疗对Graves’病~（131）I治疗后短期内血清TRAb变化的影响

目的：探讨131I治疗前行抗甲状腺药物治疗Graves’病患者对131I治疗后短期内血清TRAb变化的影响。方法：选取于我科接受131I治疗的Graves’病患者183例,分为两组：单纯131I治疗组74例与ATD组109例（131I治疗前曾接受规范ATD治疗,治疗时间〉1.5年）。采用放射免疫分析分别检测两组131I治疗前及治疗后3、6个月血清TRAb水平。结果：两组病例131I治疗后血清TRAb水平较治疗前均明显增高（P〈0.001）;131I治疗后3个月及6个月两组血清TRAb水平之间差异无统计学意义（P〉0.05）。结论：131I治疗后3个月及6个月血清TRAb水平较治疗前明显增高;且前期行抗甲状腺药物治疗对Graves’病131I治疗后短期内血清TRAb值无影响。

The Short-Term Effect of Pretreatment with ATD on Serum Thyrotrophic-Receptor Auto Antibodies Levels After ~(131)I Therapy in Patients with Graves' Disease

Objective To evaluate the short-term effect of pretreatment with ATD on serum TRAb levels after 131I therapy in patients Graves＇ disease.Methods Serum TRAb levels were measured with radioimmunoassay both before and 3 or 6 months after 131I treatment in ① 74 patients frented with 131I therapy only and ② 109 patients who had been freated with standard ATD regimen for 1.5 years before the present 131I therapy.Results After treatment,the serum TRAb levels in both two groups increased significantly than the levels before（P0.001）.There were no significant differences between the two groups 3 and 6 months after treatment（P0.05）.Conclusion 3 and 6 months after 131I therapy,serum TRAb levels were significantly higher than those before treatment in both groups.There is no short-term effect of ATD pretreatment on serum TRAb levels after 131I therapy in patients with Graves＇ disease.